CN109157533A - Application of the atractylone in preparation anti-liver cancer and anti-molecular target drug - Google Patents
Application of the atractylone in preparation anti-liver cancer and anti-molecular target drug Download PDFInfo
- Publication number
- CN109157533A CN109157533A CN201811264979.8A CN201811264979A CN109157533A CN 109157533 A CN109157533 A CN 109157533A CN 201811264979 A CN201811264979 A CN 201811264979A CN 109157533 A CN109157533 A CN 109157533A
- Authority
- CN
- China
- Prior art keywords
- atractylone
- liver cancer
- application
- drug
- molecular target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The atractylone indicated the invention discloses structure formula (I) is preparing the application in anti-liver cancer and anti-molecular target drug.From the point of view of cell experiment and results of animal of the invention, atractylone have inhibit liver cancer cells invasion transfer property and effect be present invention firstly discovers that, and also further demonstrate that atractylone has the function of inhibiting hepatocellular carcinoma in nude mice tumour growth in animal experiments, there is significant antitumor action to nude mice, has reached the unexpected technical effect in this field.These results indicate that atractylone can be used for preparing anti-liver cancer and anti-molecular target drug, have a good application prospect and application value.(I).
Description
Technical field
The present invention relates to pharmaceutical technology fields, and in particular to the medicine of traditional Chinese medicine monomer atractylone (Atractylon) is new to be used
On the way more particularly to atractylone is preparing the application in anti-liver cancer and anti-molecular target drug.
Background technique
Primary carcinoma of liver is one of highest malignant tumour of the death rate, carrys out high risks to people of other countries' health care belt.
It is counted according to the World Health Organization in 2013, the death toll that primary carcinoma of liver causes is 775517 people, China's death toll accounting
It is primary carcinoma of liver severely afflicated area more than 50%.
Liver cancer treatment there is no specific drug at present, substantially use comprehensive therapeutic plan, such as use targeted drug Suo Lafei
Buddhist nun, chemotherapy and comprehensive anti symptom treatment, control growth and metastasis of tumours with this, extend patient survival.All exist both at home and abroad at present
Correlative study is actively developed, to find the molecular target of liver cancer treatment, researches and develops molecular target drug.Traditional Chinese medicine monomer is as potential
The research of drug targets is one of direction.
For the treatment of primary carcinoma of liver, Chinese medicine also has certain method, and patient is made to mitigate clinical symptoms, extends existence
Phase.But unified medicine typing and treatment method are not yet formed at present, and the mechanism of action of Chinese medicine used is even more smudgy,
This is a big defect of Chinese medicine treatment, and hinders a big reason of Chinese medicine development.
Rhizoma atractylodis are catananche's Atractylis lancea Atractylodes Lancea (Thunb.) DC. or Atractylis chinensis
The dry tuber of Atractylodes Chinensis (DC.) Koidz., is the constituent of many Chinese medicinal formulaes, is had anti-
Viral, anti-inflammatory, liver protection and anticancer function.
Atractylone is the sequiterpene main component extracted from rhizoma atractylodis.Atractylone molecular formula C15H20O, chemical structural formula are shown in
(I).
Research about atractylone in liver cancer field is considerably less, and only Shenzhen University (Guo Nannan, 2015) has studied rhizoma atractylodis at present
Influence of the ketone to hepatocellular carcinoma H22 apoptosis, discovery atractylone are able to suppress the growth of HepG2 cell.But the slightly aobvious letter of the research
Single and not rigorous enough, mechanism of action is not also furtherd investigate, and specific defect is mainly reflected in terms of following two: first, it grinds
Study carefully only for hepatocellular carcinoma H22.Other liver cancer cells (such as MHCC97H, SMCC7721 etc.) are not studied, not
It can prove that in other liver cancer cells it is inevitable effective, so result has certain contingency, convincingness is not strong.Second,
Do not carry out animal experiment study.As it is known by the man skilled in the art that the success of cell experiment is not meant to that zoopery must
So success, this is because cell line has relatively stable and uniform physicochemical environment, what is obtained is theoretical knot ideally
Fruit；And animal body is just much more complex, more representative of under actual conditions as a result, therefore having stronger convincingness.This is also to be
What many target agents effect on cell is fine, but can not be the reason of obtaining same effect on animal.Similarly, cell is real
It verifies bright atractylone and is able to suppress the growth of HepG2 cell, be not meant to that anti-liver cancer and anti-molecular target can be necessarily made in atractylone
Drug, so it is very necessary for carrying out zoopery.
It there is no animal experiment study of the atractylone in terms of anti-liver cancer and anti-at present, also not to atractylone in anti-liver cancer and anti-molecular target
The specific research applied in mark drug.
Due to finding new potential molecular target drug by basic research currently without the specific drug for being directed to liver cancer
Very it is necessary to traditional Chinese medicine provides important references to find molecular target drug.
The present invention by rigorously comprehensively designing, systematically have studied effect that atractylone shifts Hepatocarcinoma Proliferation and
Dosage effect, so that it is determined that the internal Function and its mechanisms of atractylone.
Summary of the invention
The technical problems to be solved by the invention, are the novel medical uses for proposing atractylone, i.e. atractylone is preparing anti-liver
Application in cancer molecular target drug.
The present invention extracts the atractylone (structure formula (I)) of isolated sufficient amount from rhizoma atractylodis, passes through pharmacological evaluation, it was demonstrated that
The atractylone that following structural formula (I) indicates can be used in preparing anti-liver cancer and anti-molecular target drug.
In order to solve the above technical problems, the present invention adopts the following technical scheme:
The present invention provides the atractylone that following structural formula (I) is indicated and is preparing the application in anti-liver cancer and anti-molecular target drug.
Preferably, the atractylone has the function of inhibiting liver cancer cells invasion transfer, and the anti-liver cancer and anti-molecular target drug is
With the drug for inhibiting liver cancer cells invasion forwarding function.
Preferably, the liver cancer cells are MHCC97H cell and HepG2 cell.
It is furthermore preferred that it is 20uM that the atractylone, which inhibits the optimum effective dose of liver cancer cells invasion transfer,.
Preferably, the atractylone has the function of inhibiting hepatocellular carcinoma in nude mice tumour growth, the anti-liver cancer and anti-molecular target medicine
Object is with the drug for inhibiting hepatic carcinoma growth function.
It is furthermore preferred that it is 10mg/kg that the atractylone, which inhibits the optimum effective dose of hepatocellular carcinoma in nude mice tumour growth,.
Preferably, the atractylone has the function of reducing the intracorporal anti-liver cancer and anti-molecular marker Ki-67 expression of mouse tumor, institute
Stating anti-liver cancer and anti-molecular target drug is with the drug for reducing internal anti-liver cancer and anti-molecular marker Ki-67 expressive function.
Preferably, the anti-liver cancer and anti-molecular target drug contains the atractylone of pharmaceutical effective amount and pharmaceutically acceptable
Carrier.
By pharmaceutical technology commonly used in the art, the drug can be made into any pharmaceutically acceptable dosage form.
Preferably, the pharmaceutically acceptable dosage form of any one includes suspension, emulsion, tablet, capsule, granule, takes orally
Liquid, injection etc..
The study find that atractylone processing liver cancer cells (MHCC97H, HepG2, SMCC7721) proliferation and vigor by
Obvious to inhibit, the level of apoptosis of liver cancer cells (MHCC97H, HepG2) significantly improves, especially present invention firstly discovers that rhizoma atractylodis
Ketone has the new property for inhibiting liver cancer cells invasion transfer.Molecular indexes detection display apoptosis-related protein (Bcl-2, Bax,
Cleaved caspase-3) and invasion metastasis related protein (MMP-2, MMP-9, TIMP-2) have in atractylone processing group
Significant changes explain the mechanism that atractylone promotes Apoptosis and inhibits liver cancer cells invasion transfer from molecular level.
Results of animal shows the nude mice knurl of atractylone processing group significantly less than control group, tumor volume and weight
Statistic analysis result shows that atractylone processing group is substantially less than control group, and display atractylone has antitumor action；Ki67 mark
Object Showed by immune group result, the intracorporal Ki67 expression of nude mice tumor reduces after atractylone processing, illustrates tumor proliferation by obvious
Inhibit；HE coloration result shows that atractylone is to the heart, and liver, lung, each organ of kidney is non-toxic, illustrates that atractylone has good biology
Safety.
Compared with prior art, atractylone have inhibit liver cancer cells invasion transfer property and effect be the present invention for the first time
It was found that, and also further demonstrated that atractylone has the function of inhibiting hepatocellular carcinoma in nude mice tumour growth in animal experiments, to naked
Mouse has significant antitumor action, has reached the unexpected technical effect in this field, has had novelty and creativeness.
The present invention confirms atractylone to the good antitumor work of liver cancer from molecule, cell and animal level comprehensive result
With, and atractylone has good biological safety, and these results illustrate atractylone answering in preparation liver cancer molecular target drug
There is bright prospects and high application value in.
Detailed description of the invention
Fig. 1 be in test example 1 of the present invention atractylone to the effect schematic diagram of hepatoma cell proliferation.
Fig. 2 be in test example 1 of the present invention atractylone to the effect schematic diagram of liver cancer cells Clone formation.
Fig. 3 is the schematic diagram that atractylone promotes hepatoma cell apoptosis in test example 2 of the present invention.
Fig. 4 is apoptosis-related protein testing result schematic diagram in test example 2 of the present invention.
Fig. 5 is the effect schematic diagram that atractylone shifts liver cancer cells invasion in test example 3 of the present invention.
Fig. 6 is invasion metastasis related protein testing result schematic diagram in test example 3 of the present invention.
Fig. 7 be in test example 4 of the present invention atractylone to nude mice knurl inhibiting effect schematic diagram.
Fig. 8 is nude mice tumor volume and weight statistical result schematic diagram in test example 4 of the present invention.
Fig. 9 is Ki67 marker ImmunohistochemistryResults Results schematic diagram in test example 5 of the present invention.
Figure 10 is nude mice conscience lung kidney HE coloration result schematic diagram in test example 5 of the present invention.
Specific embodiment
Following tests example and reagent used in the examples, reagent, consumptive material, instrument, cell and animal are described as follows:
1. reagent, reagent, consumptive material, instrument
Atractylone entrusts Rui Fensi Biotechnology Co., Ltd in Chengdu to extract and purify, purity 96.72%.
Superclean bench originates from the production of Esco company of Singapore, and CO2 incubator originates from U.S. Thermo electron
Corporation company, just set/inverted fluorescence microscope originates from Japanese Olympus company, flow cytometer originates from U.S. BD public affairs
Department, low speed autobalancing centrifuge originate from Hunan Xiang Yi centrifuge Instrument Ltd..
DMEM culture medium is purchased from Shanghai Suo Laibao Biotechnology Co., Ltd, mycillin, fetal calf serum, DMSO, pancreatin
Digestive juice is purchased from Gibco company of the U.S..Annexin V/PI dye liquor, Matrigel are purchased from U.S. company BD.Transwell
Cell is purchased from U.S. Millipore company.MTS is purchased from eastern Renhua subject skill (Shanghai) Co., Ltd..
Bcl-2, Bax, cleaved caspase-3, MMP-2, MMP-9, TIMP-2, Ki67, GAPDH antibody are purchased from beauty
Abcam company of state.
2. cell, animal
Liver cancer cell lines MHCC97H, HepG2, SMCC7721 are purchased from Shanghai Inst. of Life Science, CAS cellular resources
Center.Nude mice is purchased from Beijing Beijing HFK Bio-Technology Co., Ltd..
The present invention is further illustrated with the pharmacology of atractylone and activity experiment and result below by test example.
1. atractylone of test example inhibits hepatoma cell proliferation and vigor
1, experimental group: 4 groups of atractylone concentration gradient processing, 0,5,10,20uM, wherein 0uM is the control group that atractylone is not added,
That be added is 0.2%DMSO.
2, cell proliferation experiment (mtt assay)
The cell dissociation of different pharmaceutical concentration processing is inoculated in 96 orifice plates, every 100 μ l(3000 of hole culture solution total volume
Cells)；37 DEG C are placed in, is cultivated in CO2 incubator, it is adherent to cell, culture medium is replaced, every hole, which is added, is mixed with 10% MTS detection
The culture solution of reagent, 37 DEG C of 1 h of incubation detect absorbance after taking out equilibrium at room temperature from incubator at 490 nm, detect respectively
24 h, 48h and tri- time point cell viabilities of 72h.Draw cell growth curve, statistical analysis.
3, colony formation
(1) cell inoculation
It inhales and abandons culture medium, pancreatin working solution collects cell respectively, and after washing 2 times with conditioned medium, cell is suspended in condition training
It supports in base, counts 3 times, take mean value, adjustment concentration of cell suspension to 1 x103/ml.4ml culture solution is added in 6 well culture plates,
After balancing in C02 incubator, 0.4ml cell suspension (400 cells) is added in every hole, final volume 3ml.Ten word direction when inoculation
Culture plate is rocked, vibration culture edges of boards are evenly distributed as much as possible cell.
(2) cell culture
Cell is cultivated 2~3 weeks at the standard conditions, every 3 days replacement conditioned mediums, observes Clone formation situation.
(3) clone's dyeing
Culture is terminated when cell forms macroscopic clone (each clone cell number is at 50-150 or so).Discard culture
Base after carefully embathing cell 2 times with PBS, is added the hole paraformaldehyde 1ml/, after fixing 10min, discards fixer, slow with flowing water
Slowly it rinses well, the crystal violet liquid that lml is added in every hole dyes 30min, slowly washes away dyeing liquor, drying in draught cupboard with flowing water.
(4) colony count
Culture plate is placed on gel imaging system, using visible light conditions, colony counts, scanning are counted with random institute's band software
And save image.Cloning efficiency (%)=colony counts/inoculating cell number x100%.Cloning efficiency (%) adjusted=gram
Grand formation rate (%)/control group cloning efficiency (%).
Experimental result is as depicted in figs. 1 and 2, illustrates: atractylone processing is to MHCC97H and HepG2 cell Proliferation and clone
Formation inhibitory effect is preferable, and 20uM dose effect is best.Therefore subsequent cell experiment is using this two plants of cells as research object.
2. atractylone of test example promotes hepatoma cell apoptosis
The bis- dye methods of Annexin V-FITC/PI, grouping are same as above, and cell is MHCC97H and HepG2.
(1) suspension cell is directly collected into the centrifuge tube of 10 ml, and every sample cell number is (1~5) × 106/ml.
(2) 500~1000 r/min are centrifuged 5 min, discard culture solution.1 time is washed with incubation buffer, 500~1000r/min
It is centrifuged 5min.Cell is resuspended with the label solution of 100 ul, is protected from light 10~15min of incubation, 500~1 000 r/min at room temperature
It is centrifuged 5 min sedimentation cell incubation buffers to wash 1 time, is added at 4 DEG C of fluorescent solutions and is incubated for 20 min, be protected from light and vibrate frequently.
488 nm of flow cytometer excitation wavelength detect FITC fluorescence, another wavelength with the passband filter that a wavelength is 515 nm
Filter greater than 560 nm detects PI.
(3) Western blot detects apoptosis-related protein (Bcl-2, Bax, cleaved caspase-3), internal reference albumen
For GAPDH.
As a result as shown in Figure 3 and Figure 4, these results suggest that: atractylone can remarkably promote hepatoma cell apoptosis, 20uM agent
Dose-effect fruit is best.
3. atractylone of test example inhibits liver cancer cells invasion transfer
Grouping is same as above, and cell is MHCC97H and HepG2.
It takes Matrigel glue to melt on ice, the dilution proportion of 1:6 is pressed with the serum free medium of pre-cooling；It takes and dilutes
The cell Transwell of the Matrigel glue 100ul poly- carbon ester film of 8um that is carefully vertically added to pre-cooling (to grasp on ice
Make)；24 orifice plates for completing glue are put into 37 DEG C of incubators and are incubated for 2h；Cell suspension 100ul(density is added after gelling is solid
Subsequent experimental is carried out for 1 × 106/ml)；Carry out dyeing observation within cell culture 24 hours；It randomly selects 6 visuals field to count, and unites
Count result.
Western blot detection invasion metastasis related protein (MMP-2, MMP-9, TIMP-2), internal reference albumen are GAPDH.
As a result as shown in Figure 5 and Figure 6, these results suggest that: atractylone can significantly inhibit liver cancer cells invasion transfer,
20uM dose effect is best.
4. atractylone of test example inhibits the growth of nude mice knurl
Cell: HepG2, for constructing nude mice by subcutaneous tumor
Animal: nude mice, 6-8 week old are purchased from Beijing Beijing HFK Bio-Technology Co., Ltd..
The setting of drug-treated concentration gradient: 0,5,10mg/kg, totally three groups.Wherein 0mg/kg is the control that atractylone is not added
Group, addition is 0.2%DMSO(dimethyl sulfoxide).
(1) nude mice (18g or so) for selecting 6-8 week old, raises in the environment of SPF rank, adapts to environment 5-7 days, to
Weight is inoculated with after reaching 20g or so.
(2) expand culture cell, digested with pancreatin, collect cell.It is washed 2-3 times with the culture medium without serum and antibiotic
After count.Use to be seeded on ice is put after being suspended uniformly.
(3) it is inoculated respectively in the left dorsal subcutaneous of each group nude mice, 100 μ l cell suspensions (1 × 107 cell/
Only).
(4) it is observed after being inoculated with, position to be seeded is randomly divided into 3 groups (6/group) when growing tumour (about 50-100 mm3):
Control group, 5mg/kg group, 10mg/kg group.
(5) grouping (the 0th day) record nude mouse tumor size of the same day, continuous 3 weeks.
(6) daily into observation nude mice meal situation, mechanics, tumor size and Survival.Use vernier calliper within every 3 days
Ruler measures a gross tumor volume (see figure 7), draws tumor growth curve (see figure according to the gross tumor volume average value being calculated
8).
As shown in Figs. 7-8, the above result of study explanation: atractylone processing nude mice can effectively inhibit liver cancer knurl raw
Long, tumor volume and weight are substantially less than control group, and wherein 10mg/kg dosage group tumor inhibitory effect is best.
5. atractylone pathology of test example and molecular studies
(1) disconnected neck is carried out to the nude mice for completing test example 4 to put to death, tumor tissues is taken to be taken pictures and weighed；
(2) tumor tissues do immunohistochemistry, detect the expression of Ki-67 marker, as a result see Fig. 9；
(3) coring, liver, lung, nephridial tissue do HE dyeing, carry out organ toxicity's safety evaluation, the result is shown in Figure 10.
As shown in Figure 9, Figure 10, these results suggest that: nude mice tumor intracorporal Ki67 expression reduces after atractylone processing, from disease
Reason and molecular level illustrate that tumor proliferation ability is inhibited (see figure 9) by obvious.The heart (Heart), liver (Lung), lung
(Liver), the HE coloration result of kidney (Kidney) is shown, atractylone processing group and control group illustrate pair without obvious pathological change
Each organ is non-toxic, and atractylone has good biological safety (see Figure 10).
The study find that the nude mice knurl of atractylone processing group is significantly less than control group, tumor volume and weight statistical
Atractylone processing group is substantially less than control group as the result is shown for analysis, and display atractylone has antitumor action；Ki67 marker is immune
Groupization illustrates that tumor proliferation is obviously inhibited the results show that the intracorporal Ki67 expression reduction of nude mice tumor after atractylone processing；HE
Coloration result shows that atractylone is to the heart, and liver, lung, each organ of kidney is non-toxic, illustrates that atractylone has good biological safety.
This research from animal, pathology, molecular level synthesis result confirm atractylone to the good antitumor action of liver cancer,
And atractylone has good biological safety, and these results illustrate atractylone in the application of preparation liver cancer molecular target drug
With bright prospects and high application value.
The present invention is further illustrated below by way of embodiment is prepared further
The preparation of embodiment 1, atractylone tablet
Every dosage of ingredient
Atractylone 50mg
Dextrin 37.45mg
Microcrystalline cellulose 10.5mg
Starch 17.5mg
Lactose 10.5mg
Magnesium stearate 1.05mg
Dextrin, microcrystalline cellulose, starch, lactose is added in atractylone (being made by 1 method of embodiment) by recipe quantity to mix, is made
Magnesium stearate is added in particle, mixes, and tabletting is to get (every contains atractylone 0.05g).Adult recommends oral 1-4 pieces/times of dosage,
Daily 2 ~ 3 times.
The preparation of embodiment 2, atractylone capsule
Every dosage of ingredient
50 mg of atractylone
37.45 mg of dextrin
10.5 mg of microcrystalline cellulose
17.5 mg of starch
10.5 mg of lactose
Dextrin, microcrystalline cellulose, starch, lactose (is made) in atractylone by recipe quantity to mix by 1 method of embodiment, particle is made
Afterwards, it is filled into No. 0 hard capsule case, polishing obtains (every capsule contains atractylone 0.05g).Adult recommends oral dosage 1-4
Tablet/time, daily 2 ~ 3 times.
Claims (10)
1. application of the atractylone that following structural formula (I) indicates in preparation anti-liver cancer and anti-molecular target drug,
。
2. application as described in claim 1, which is characterized in that the atractylone has the function for inhibiting liver cancer cells invasion transfer
Can, the anti-liver cancer and anti-molecular target drug is with the drug for inhibiting liver cancer cells invasion forwarding function.
3. application as claimed in claim 2, which is characterized in that the liver cancer cells are MHCC97H cell and HepG2 cell.
4. application as claimed in claim 2, which is characterized in that the atractylone inhibits most preferably having for liver cancer cells invasion transfer
Effect dosage is 20uM.
5. application as described in claim 1, which is characterized in that the atractylone has the function for inhibiting hepatocellular carcinoma in nude mice tumour growth
Can, the anti-liver cancer and anti-molecular target drug is with the drug for inhibiting hepatic carcinoma growth function.
6. application as claimed in claim 5, which is characterized in that the atractylone inhibits most preferably having for hepatocellular carcinoma in nude mice tumour growth
Effect dosage is 10mg/kg.
7. application as described in claim 1, which is characterized in that the atractylone has the reduction intracorporal anti-liver cancer and anti-molecule of mouse tumor
The function of marker Ki-67 expression, the anti-liver cancer and anti-molecular target drug are that have to reduce internal anti-liver cancer and anti-molecular marker Ki-
The drug of 67 expressive functions.
8. application as described in claim 1, which is characterized in that the anti-liver cancer and anti-molecular target drug contains pharmaceutical effective amount
Atractylone and pharmaceutically acceptable carrier.
9. application as described in claim 1, which is characterized in that the drug is made into pharmaceutically acceptable dose any
Type.
10. application as claimed in claim 9, which is characterized in that the pharmaceutically acceptable dosage form of any one includes mixed
Suspension, emulsion, tablet, capsule, granule, oral solution, injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811264979.8A CN109157533A (en) | 2018-10-29 | 2018-10-29 | Application of the atractylone in preparation anti-liver cancer and anti-molecular target drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811264979.8A CN109157533A (en) | 2018-10-29 | 2018-10-29 | Application of the atractylone in preparation anti-liver cancer and anti-molecular target drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109157533A true CN109157533A (en) | 2019-01-08 |
Family
ID=64875408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811264979.8A Pending CN109157533A (en) | 2018-10-29 | 2018-10-29 | Application of the atractylone in preparation anti-liver cancer and anti-molecular target drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109157533A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111410641A (en) * | 2020-03-03 | 2020-07-14 | 黑龙江中医药大学 | Atractylodes macrocephala lactone polymer with antitumor activity and preparation method and application thereof |
| CN114129555A (en) * | 2020-09-04 | 2022-03-04 | 中国科学院大连化学物理研究所 | Application of atractylone or atractylodin as FFA1 agonist and pharmaceutical composition |
| CN114452280A (en) * | 2021-11-11 | 2022-05-10 | 杭州师范大学 | Application of atractylone in preparation of Sirt3 gene activator |
| CN116173011A (en) * | 2023-02-23 | 2023-05-30 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | Inhibitor for targeting SLC11A2 and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857358A (en) * | 2005-04-30 | 2006-11-08 | 广州中医药大学 | Use of atractylone, atractylone-containing plant and atractylone extract in preparing influenza virus resisting medicine |
-
2018
- 2018-10-29 CN CN201811264979.8A patent/CN109157533A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857358A (en) * | 2005-04-30 | 2006-11-08 | 广州中医药大学 | Use of atractylone, atractylone-containing plant and atractylone extract in preparing influenza virus resisting medicine |
Non-Patent Citations (4)
| Title |
|---|
| JOSÉ F. CICCIÓ ET AL.: "Volatile compounds of Nectandra salicina (lauraceae) from Costa Rica and their cytotoxic activity on cell lines", 《QUIM. NOVA》 * |
| RUNWEI YAN ET AL.: "Cytotoxicity and antibacterial activity of Lindera strychnifolia essential oils and extracts", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
| 胡翠英等: "利用Autodock预测苍术酮的潜在抗肿瘤靶点", 《生物技术》 * |
| 郭楠楠: "苍术酮对体外培养肝癌细胞HepG2抑制作用", 《安徽农业科学》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111410641A (en) * | 2020-03-03 | 2020-07-14 | 黑龙江中医药大学 | Atractylodes macrocephala lactone polymer with antitumor activity and preparation method and application thereof |
| CN114129555A (en) * | 2020-09-04 | 2022-03-04 | 中国科学院大连化学物理研究所 | Application of atractylone or atractylodin as FFA1 agonist and pharmaceutical composition |
| CN114452280A (en) * | 2021-11-11 | 2022-05-10 | 杭州师范大学 | Application of atractylone in preparation of Sirt3 gene activator |
| CN114452280B (en) * | 2021-11-11 | 2023-11-03 | 杭州师范大学 | Application of atractylone in preparation of glioma treatment drug |
| CN116173011A (en) * | 2023-02-23 | 2023-05-30 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | Inhibitor for targeting SLC11A2 and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109157533A (en) | Application of the atractylone in preparation anti-liver cancer and anti-molecular target drug | |
| Cao et al. | Ginkgo biloba exocarp extracts induces apoptosis in Lewis lung cancer cells involving MAPK signaling pathways | |
| CN104140953B (en) | Breast cancer multidrug-resistant cell strain constructed by virtue of epirubicin induction as well as construction method and application thereof | |
| CN106749343B (en) | A kind of acylhydrazone schiff bases copper complex-human serum albumins compound and its application | |
| CN110433290A (en) | Cryptotanshinone and the combination of TKI inhibitor are preparing the application in Ph+ acute lymphoblastic leukemia chemotherapeutics | |
| CN109232718A (en) | A kind of synthetic peptide sp2 and its application | |
| CN101756957B (en) | Pharmaceutical composition containing artemisinin, artemisinin derivatives and histon deacetylase (HDAC) inhibitor and application thereof | |
| CN102552908A (en) | Pharmaceutical composition containing artemisinin, artemisinin derivatives and Bcl-2 inhibitor and application thereof | |
| Alsawalha et al. | Anti-diabetic activities of Dactylorhiza hatagirea leaf extract in 3T3-L1 cell line model | |
| CN109674866A (en) | A kind of anti-human primary gastrointestinal cancers pharmaceutical composition, preparation method and applications | |
| CN102441168B (en) | Medicine composition containing apigenin, apigenin derivant and Bc1-2 inhibitor and application thereof in preparation of medicines capable of treating cancer | |
| CN102688493A (en) | Pharmaceutical composition containing resveratrol, resveratrol derivative and Bc1-2 inhibitor, and application thereof | |
| CN108303552A (en) | Detection method of the cucoline to pancreatic carcinoma SW1990 Proliferation and apoptosis | |
| CN104887650A (en) | New use of isoliquiritigenin and derivative | |
| CN108553455B (en) | Application of trialdehyde phloroglucinol thiosemicarbazone heterozygote compound in antitumor drugs | |
| WO2012103783A1 (en) | Use of artemisine derivatives and pharmaceutical salts thereof | |
| CN105061533B (en) | Hexa methoxy flavanone rhamnopyranosyl rhamnoside and its application | |
| CN108451965A (en) | A kind of radix paeoniae rubra terpene glycoside composition and preparation method thereof with function of resisting myocardial ischemia | |
| JP4896445B2 (en) | Composition for preventing and / or treating adenocarcinoma comprising garlic processed product | |
| CN110478346A (en) | Antineoplastic pharmaceutical compositions and its application | |
| CN108451905A (en) | A kind of gambogicacid nano-emulsion preparation of high-efficiency low-toxicity and its preparation method and application | |
| CN113368090B (en) | Application of 3, 4-seco cycloartenane type tetracyclic triterpene compound or pharmaceutically acceptable salt thereof in preparation of anticancer drugs | |
| CN110179915A (en) | Application of the Shenmai injection in the drug resistance drug that preparation reverses antineoplastic | |
| CN104208074B (en) | Purposes of the 2 α hydroxyl protopanoxadiols in tumor multi-drug resistance reversal agents are prepared | |
| CN102836160A (en) | Combined medicament for treating cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190108 |
|
| WD01 | Invention patent application deemed withdrawn after publication |